miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer

被引:88
作者
Chen, Bo [1 ,2 ]
Tang, Hailin [1 ,2 ]
Liu, Xiaoping [1 ,2 ]
Liu, Peng [1 ,2 ]
Yang, Lu [1 ,2 ]
Xie, Xinhua [1 ,2 ]
Ye, Feng [1 ,2 ]
Song, Cailu [1 ,2 ]
Xie, Xiaoming [1 ,2 ]
Wei, Weidong [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Ctr Canc, Dept Breast Oncol, Guangzhou 510275, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510275, Guangdong, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
miR-22; GLUT1; Breast cancer; Prognostic factor; GASTRIC-CANCER; EXPRESSION; PROGRESSION; PROLIFERATION; TRANSCRIPTION; MICRORNA-22; INVASION;
D O I
10.1016/j.canlet.2014.09.028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It has been reported that miR-22 plays an important role and may be a promising therapeutic target in cancer. In this study, we found that GLUT1 is a direct target of miR-22. The ectopic expression of miR-22 inhibited breast cancer cell proliferation and invasion by targeting GLUT1. A reverse correlation between the expression of miR-22 and GLUT1 was observed in breast cancer tissue samples. Furthermore, miR-22 was significantly correlated with the TNM stage, local relapse, distant metastasis, and survival of breast cancer patients. Our data suggest that miR-22 functions as a tumor suppressor and is a promising prognostic biomarker in breast cancer. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:410 / 417
页数:8
相关论文
共 24 条
[1]   miR-22 Forms a Regulatory Loop in PTEN/AKT Pathway and Modulates Signaling Kinetics [J].
Bar, Nadav ;
Dikstein, Rivka .
PLOS ONE, 2010, 5 (05)
[2]   MicroRNAs: Target Recognition and Regulatory Functions [J].
Bartel, David P. .
CELL, 2009, 136 (02) :215-233
[3]   Metastatic Breast Cancer, Version 1.2012 Featured Updates to the NCCN Guidelines [J].
Carlson, Robert W. ;
Allred, D. Craig ;
Anderson, Benjamin O. ;
Burstein, Harold J. ;
Edge, Stephen B. ;
Farrar, William B. ;
Forero, Andres ;
Giordano, Sharon Hermes ;
Goldstein, Lori J. ;
Gradishar, William J. ;
Hayes, Daniel F. ;
Hudis, Clifford A. ;
Isakoff, Steven Jay ;
Ljung, Britt-Marie E. ;
Mankoff, David A. ;
Marcom, P. Kelly ;
Mayer, Ingrid A. ;
McCormick, Beryl ;
Pierce, Lori J. ;
Reed, Elizabeth C. ;
Smith, Mary Lou ;
Soliman, Hatem ;
Somlo, George ;
Theriault, Richard L. ;
Ward, John H. ;
Wolff, Antonio C. ;
Zellars, Richard ;
Kumar, Rashmi ;
Shead, Dorothy A. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (07) :821-829
[4]   MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents [J].
Cochrane, Dawn R. ;
Spoelstra, Nicole S. ;
Howe, Erin N. ;
Nordeen, Steven K. ;
Richer, Jennifer K. .
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (05) :1055-1066
[5]   miR-22 is down-regulated in gastric cancer, and its overexpression inhibits cell migration and invasion via targeting transcription factor Sp1 [J].
Guo, Mei-Mei ;
Hu, Li-Hua ;
Wang, Yong-Qiang ;
Chen, Peng ;
Huang, Jian-Guo ;
Lu, Ning ;
He, Jiang-Hong ;
Liao, Cheng-Gong .
MEDICAL ONCOLOGY, 2013, 30 (02)
[6]   Glut-1 Expression Correlates with Basal-like Breast Cancer [J].
Hussein, Yaser R. ;
Bandyopadhyay, Sudeshna ;
Semaan, Assaad ;
Ahmed, Quratulain ;
Albashiti, Bassam ;
Jazaerly, Tarek ;
Nahleh, Zeina ;
Ali-Fehmi, Rouba .
TRANSLATIONAL ONCOLOGY, 2011, 4 (06) :321-327
[7]  
Józwiak P, 2012, POSTEP HIG MED DOSW, V66, P165, DOI 10.5604/17322693.988242
[8]   Progressive increase of glucose transporter-3 (GLUT-3) expression in estrogen-induced breast carcinogenesis [J].
Kocdor, M. A. ;
Kocdor, H. ;
Pereira, J. S. ;
Vanegas, J. E. ;
Russo, I. H. ;
Russo, J. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (01) :55-64
[9]   miRNAs as Modulators of Angiogenesis [J].
Landskroner-Eiger, Shira ;
Moneke, Isabelle ;
Sessa, William C. .
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2013, 3 (02)
[10]   Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer [J].
Macheda, ML ;
Rogers, S ;
Best, JD .
JOURNAL OF CELLULAR PHYSIOLOGY, 2005, 202 (03) :654-662